Cost burden of diffuse large B-cell lymphoma

References

• Teras LR, DeSantis CE, Cerhan JR, et al. US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016 Sep 12;66(6):443–459.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019 Jun 11;1–23.
   Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017 Oct 19;130(16):1800–1808.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000 Feb 3;403(6769):503–511.
   PubMed Web of Science ®Google Scholar
• Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017 Oct 5;171(2):481–494.e15.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018 Apr 12;378(15):1396–1407.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 May;24(5):679–690.
   PubMed Web of Science ®Google Scholar
• Arthur SE, Jiang A, Grande BM, et al. Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nat Commun. 2018 Oct 1;9(1):4001.
   PubMedGoogle Scholar
• Heward JA, Kumar EA, Korfi K, et al. Precision medicine and lymphoma. Curr Opin Hematol. 2018 Jul;25(4):329–334.
   PubMed Web of Science ®Google Scholar
• Patel SP, Harkins RA, Lee MJ, et al. Using informatics tools to characterize precision medicine treatments for Diffuse Large B-Cell Lymphoma (DLBCL) [Abstract]. Blood. 2018;132.
   Web of Science ®Google Scholar
• Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017 Dec 28;377(26):2545–2554.
   PubMed Web of Science ®Google Scholar
• NCCN. National Comprehensive Cancer Center Clinical Practice Guidelines in Oncology (NCCN Guidelines): B-Cell Lymphomas, Version 3.2019; 2019.
   Google Scholar
• Vaidya R, Witzig TE. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol. 2014 Nov;25(11):2124–2133.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Trneny M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017 Nov 1;35(31):3529–3537.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Kolibaba KS, Reeves JA, et al. Randomized Phase II Study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2017 Nov 1;35(31):3538–3546.
   PubMed Web of Science ®Google Scholar
• Younes A, Zinzani PL, Sehn LH, et al. A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2014;32(15_suppl):TPS8615–TPS8615.
   Web of Science ®Google Scholar
• Staudt LM. Precision medicine based on the genetic taxonomy of DLBCL. Plenary Session 1: are we ready for lymphoma MATCH trials? American Association for Cancer Research; 2018. Available from: https://webcast.aacr.org/s/2018lym/PL01;jsessionid=9A4C05B787ED1034B60F428371A3957B
   Google Scholar
• Younes A. How to design a MATCH trial for lymphoma. Plenary Session 1: are we ready for lymphoma MATCH trials? American Association for Cancer Research; 2018. Available from: https://webcast.aacr.org/s/2018lym/PL01;jsessionid=9A4C05B787ED1034B60F428371A3957B
   Google Scholar
• Cohen JB, Behera M, Thompson CA, et al. Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma. Blood. 2017 Feb 2;129(5):561–564.
   PubMed Web of Science ®Google Scholar
• Thompson CA, Charlson ME, Schenkein E, et al. Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Ann Oncol. 2010 Nov;21(11):2262–2266.
   PubMed Web of Science ®Google Scholar
• Thompson CA, Ghesquieres H, Maurer MJ, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol. 2014 Nov 1;32(31):3506–3512.
   PubMed Web of Science ®Google Scholar
• NCI. FDA Approves Second CAR T-Cell Therapy for Lymphoma; 2018 [cited 2019]. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2018/tisagenlecleucel-fda-lymphoma
   Google Scholar
• Sehn LH, Herrera AF, Matasar MJ, et al. Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): updated Results of a Phase (Ph) Ib/II Study. Poster session presented at 60th ASH Annual Meeting and Exposition; 2018 Dec 1–4; San Diego, CA.
   Google Scholar
• Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin. 2010 Nov–Dec;60(6):393–408.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Ghesquieres H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014 Apr 1;32(10):1066–1073.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019 Jan 3;380(1):45–56.
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011 Jan 19;103(2):117–128.
   PubMed Web of Science ®Google Scholar
• NCI. NCI Cancer Trends Progress Report: Financial Burden of Cancer Care; 2019. Available from: https://progressreport.cancer.gov/after/economic_burden
   Google Scholar
• XE. XE Current and Historical Rate Tables; 2019. Available from: https://www.xe.com/currencytables/
   Google Scholar
• BLS. US Bureau of Labor Statistics Consumer Price Index Inflation Calculator. 2019. Available from: https://www.bls.gov/data/inflation_calculator.htm
   Google Scholar
• Wang HI, Smith A, Aas E, et al. Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort. Eur J Health Econ. 2017 Mar;18(2):255–267.
   PubMed Web of Science ®Google Scholar
• Morrison VA, Bell JA, Hamilton L, et al. Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA. Future Oncol. 2018 Oct;14(25):2627–2642.
   PubMed Web of Science ®Google Scholar
• Ren J, Asche CV, Shou Y, et al. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA. J Comp Eff Res. 2019 Apr;8(6):393–402.
   PubMed Web of Science ®Google Scholar
• Costa S, Scott DW, Steidl C, et al. Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia. Curr Oncol. 2019 Apr;26(2):108–113.
   PubMed Web of Science ®Google Scholar
• Lee RC, Zou D, Demetrick DJ, et al. Costs associated with diffuse large B-cell lymphoma patient treatment in a Canadian integrated cancer care center. Value Health. 2008 Mar–Apr;11(2):221–230.
   PubMed Web of Science ®Google Scholar
• Kutikova L, Bowman L, Chang S, et al. Medical costs associated with non-Hodgkin’s lymphoma in the United States during the first two years of treatment. Leuk Lymphoma. 2006 Aug;47(8):1535–1544.
   PubMed Web of Science ®Google Scholar
• Juul MB, Jensen PH, Engberg H, et al. Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study. Eur J Cancer. 2018 Aug;99:86–96.
   PubMed Web of Science ®Google Scholar
• Flowers CR, Armitage JO. A decade of progress in lymphoma: advances and continuing challenges. Clin Lymphoma Myeloma Leuk. 2010 Dec;10(6):414–423.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242.
   PubMed Web of Science ®Google Scholar
• Feugier P, Hoof AV, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the groupe d’Etude des lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117–4126.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010 Sep 23;116(12):2040–2045.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121–3127.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 May;7(5):379–391.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011 Oct;12(11):1013–1022.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22–32.
   PubMed Web of Science ®Google Scholar
• Byfield SD, Becker LK, Small A. Differences in treatment patterns and costs among diffuse large B-cell lymphoma patients treated in the clinic vs. the hospital outpatient setting. Blood. 2013;122(21):1751.
   Web of Science ®Google Scholar
• Kim J, Malin JL, Doan QV, et al. Cost-effectiveness of primary prophylaxis with pegfilgrastim versus filgrastim in non-hodgkin’s lymphoma patients receiving CHOP-21. Blood. 2007;110(11):5166.
   Web of Science ®Google Scholar
• Lyman G, Lalla A, Barron R, et al. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin’s lymphoma receiving CHOP-21 in United States. Curr Med Res Opin. 2009 Feb;25(2):401–411.
   PubMed Web of Science ®Google Scholar
• Lathia N, Isogai PK, De Angelis C, et al. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients. J Natl Cancer Inst. 2013 Aug 7;105(15):1078–1085.
   PubMedGoogle Scholar
• Hill G, Barron R, Fust K, et al. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin’s lymphoma: cost-effectiveness analyses. J Med Econ. 2014 Jan;17(1):32–42.
   PubMedGoogle Scholar
• Wang XJ, Tang T, Farid M, et al. Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (Nivestim) or pegfilgrastim is cost effective in non-hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy. PloS One. 2016;11(2):e0148901.
   PubMed Web of Science ®Google Scholar
• Fust K, Li X, Maschio M, et al. Cost-effectiveness analysis of prophylaxis treatment strategies to reduce the incidence of febrile neutropenia in patients with early-stage breast cancer or non-hodgkin lymphoma. PharmacoEconomics. 2017 Apr;35(4):425–438.
   PubMed Web of Science ®Google Scholar
• Chan KK, Siu E, Krahn MD, et al. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. J Clin Oncol. 2012 Apr 1;30(10):1064–1071.
   PubMed Web of Science ®Google Scholar
• Doorduijn JK, Buijt I, van der Holt B, et al. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin’s lymphoma. Haematologica. 2004 Sep;89(9):1109–1117.
   PubMed Web of Science ®Google Scholar
• Best JH, Hornberger J, Proctor SJ, et al. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma. Value Health. 2005 Jul–Aug;8(4):462–470.
   PubMed Web of Science ®Google Scholar
• Groot MT, Lugtenburg PJ, Hornberger J, et al. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur J Haematol. 2005 Mar;74(3):194–202.
   PubMed Web of Science ®Google Scholar
• Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer. 2005 Apr 15;103(8):1644–1651.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Ravasio R. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma. Clin Drug Investig. 2008;28(1):55–65.
   PubMed Web of Science ®Google Scholar
• Johnston KM, Marra CA, Connors JM, et al. Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada. Value Health. 2010 Sep–Oct;13(6):703–711.
   PubMed Web of Science ®Google Scholar
• Griffiths RI, Gleeson ML, Mikhael J, et al. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. Cancer. 2012 Dec 15;118(24):6079–6088.
   PubMed Web of Science ®Google Scholar
• Khor S, Beca J, Krahn M, et al. Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. BMC Cancer. 2014 Aug 12;14:586.
   PubMed Web of Science ®Google Scholar
• Coyne GO, Takebe N, Chen AP. Defining precision: the precision medicine initiative trials NCI-MPACT and NCI-MATCH. Curr Probl Cancer. 2017 May - Jun;41(3):182–193.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jun 20;346(25):1937–1947.
   PubMed Web of Science ®Google Scholar
• Read JA, Koff JL, Nastoupil LJ, et al. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):460–467.e2.
   PubMed Web of Science ®Google Scholar
• Koff JL, Flowers CR. Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: where do we go from here?. Cancer. 2017 Sep 1;123(17):3222–3225.
   PubMed Web of Science ®Google Scholar
• Davies A, Cummin TE, Barrans S, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019 May;20(5):649–662.
   PubMed Web of Science ®Google Scholar
• Younes A, Sehn LH, Johnson P, et al. Randomized Phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019 May 20;37(15):1285–1295.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Witzig TE, Gascoyne RD, et al. ROBUST: first report of phase III randomized study of lenalidomide/R-CHOP (R2-CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Hematol Oncol. 2019;37(S2):36–37.
   Google Scholar
• Nowakowski GS, Hong F, Scott DW, et al. Addition of lenalidomide to R-Chop (R2chop) improves outcomes in newly diagnosed diffuse large B-Cell lymphoma (Dlbcl): first report of ecog-acrin1412 a randomized phase 2 US Intergroup study Of R2chop Vs R-Chop. Hematol Oncol. 2019;37(S2):37–38.
   Google Scholar
• Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3879–3884.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011 Jul 27;476(7360):298–303.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011 Jul 31;43(9):830–837.
   PubMed Web of Science ®Google Scholar
• Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1398–1403.
   PubMed Web of Science ®Google Scholar
• Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010 Jul 10;28(20):3360–3365.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Jiang A, Boyle M, et al. Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2019 Jan 20;37(3):190–201.
   PubMed Web of Science ®Google Scholar
• Siu LL, Conley BA, Boerner S, et al. Next-generation sequencing to guide clinical trials. Clin Cancer Res off J Am Assoc Cancer Res. 2015 Oct 15;21(20):4536–4544.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L. The genetic basis of diffuse large B-cell lymphoma. Curr Opin Hematol. 2013 Jul;20(4):336–344.
   PubMed Web of Science ®Google Scholar
• Fang B, Mehran RJ, Heymach JV, et al. Predictive biomarkers in precision medicine and drug development against lung cancer. Chin J Cancer. 2015 Jul 2;34(7):295–309.
   PubMedGoogle Scholar
• Ribrag V, Soria J, Michot J, et al. Phase 1 study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2): preliminary safety and activity in relapsed or refractory Non-Hodgkin Lymphoma (NHL) Patients [[Abstract]]. Blood. 2015;126(23):473.
   Google Scholar
• Vermaat JS, Pals ST, Younes A, et al. Precision medicine in diffuse large B-cell lymphoma: hitting the target. Haematologica. 2015 Aug;100(8):989–993.
   PubMed Web of Science ®Google Scholar
• Bowdin S, Gilbert A, Bedoukian E, et al. Recommendations for the integration of genomics into clinical practice. Genet Med. 2016 Nov;18(11):1075–1084.
   PubMed Web of Science ®Google Scholar
• He J, Abdel-Wahab O, Nahas MK, et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood. 2016 Jun 16;127(24):3004–3014.
   PubMed Web of Science ®Google Scholar
• Warner JL, Jain SK, Levy MA. Integrating cancer genomic data into electronic health records. Genome Med. 2016 Oct 26;8(1):113.
   PubMedGoogle Scholar
• Blombery P, Lickiss J, Dickinson M. The price of success-health economics of personalized diffuse large B-cell lymphoma treatment. Leuk Lymphoma. 2018 Jul;59(7):1517–1519.
   PubMed Web of Science ®Google Scholar
• King RL, Nowakowski GS, Witzig TE, et al. Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. Blood Cancer J. 2018 Feb 28;8(3):27.
   PubMedGoogle Scholar
• Nowakowski GS, Feldman T, Rimsza LM, et al. Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. Blood Cancer J. 2019 May 16;9(6):48.
   PubMedGoogle Scholar
• Chen Q, Staton AD, Ayer T, et al. Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. Leuk Lymphoma. 2018 Jul;59(7):1700–1709.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non–germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a Phase II study. J Clin Oncol. 2015;33(3):251–257.
   PubMed Web of Science ®Google Scholar
• Dahi PB, Moskowitz CH, Giralt SA, et al. Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma. Expert Rev Hematol. 2019;18:1–12.
   Google Scholar
• Danese MD, Griffiths RI, Gleeson ML, et al. Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy. Leuk Lymphoma. 2017 May;58(5):1094–1104.
   PubMed Web of Science ®Google Scholar
• Slawsky KA, Goss TF, Shinkle R, et al. Economic burden of relapsed/refractory diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL): A review of the literature. J Clin Oncol. 2010;28(15_suppl):e18564–e18564.
   Web of Science ®Google Scholar
• Huntington S, Keshishian A, McGuire M, et al. Costs of relapsed diffuse large B-cell lymphoma among medicare patients. Leuk Lymphoma. 2018 Dec;59(12):2880–2887.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995 Dec 7;333(23):1540–1545.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010 Sep 20;28(27):4184–4190.
   PubMed Web of Science ®Google Scholar
• Epperla N, Hamadani M. Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: current controversies and advances. Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):277–284.
   PubMedGoogle Scholar
• Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell transplantation. Blood. 2012 Aug 23;120(8):1545–1551.
   PubMed Web of Science ®Google Scholar
• Preussler JM, Denzen EM, Majhail NS. Costs and cost-effectiveness of hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Nov;18(11):1620–1628.
   PubMed Web of Science ®Google Scholar
• Bentley TS, Phillips SJ. Milliman Research Report: 2017 U.S. organ and tissue transplant cost estimates and discussion; 2017.
   Google Scholar
• Hubel K, Ostermann H, Glass B, et al. Plerixafor in non-Hodgkin’s lymphoma patients: a German analysis of time, effort and costs. Bone Marrow Transplant. 2019 Jan;54(1):123–129.
   PubMed Web of Science ®Google Scholar
• Tichopad A, Vitova V, Koristek Z, et al. Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients. J Clin Apher. 2013 Dec;28(6):395–403.
   PubMed Web of Science ®Google Scholar
• Micallef IN, Sinha S, Gastineau DA, et al. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant. 2013 Jan;19(1):87–93.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Kramer C, Hogan KR, et al. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. 2012 Nov;52(11):2375–2381.
   PubMed Web of Science ®Google Scholar
• Watts NL, Marques MB, Peavey DB, et al. Mobilization of hematopoietic progenitor cells for autologous transplantation using pegfilgrastim and plerixafor: efficacy and cost implications. Biol Blood Marrow Transplant. 2019 Feb;25(2):233–238.
   PubMed Web of Science ®Google Scholar
• Sung AD, Grima DT, Bernard LM, et al. Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone. Bone Marrow Transplant. 2013 Nov;48(11):1444–1449.
   PubMed Web of Science ®Google Scholar
• Cho SK, McCombs J, Punwani N, et al. Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States. Leuk Lymphoma. 2019;8:1–7.
   Google Scholar
• Nakamura A, Kojima Y, Miyazawa K, et al. Clinical impact of aprepitant in patients receiving high-dose chemotherapy prior to autologous peripheral blood stem cell transplantation: a cost-effectiveness analysis. Oncology. 2017;93(5):302–308.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Johnson HR, Kaufman JL, et al. Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Jun;20(6):852–857.
   PubMed Web of Science ®Google Scholar
• Ianotto JC, Ngo Sack F, Couturier MA, et al. Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery. Leuk Lymphoma. 2014 Jan;55(1):74–77.
   PubMed Web of Science ®Google Scholar
• Sheth V, Gore A, Jain R, et al. Pegfilgrastim: more cost effective and equally efficacious option as compared to filgrastim in autologous stem cell transplant. Indian J Hematol Blood Transfusion. 2019 Jan;35(1):66–71.
   PubMed Web of Science ®Google Scholar
• Sebban C, Lefranc A, Perrier L, et al. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study). Eur J Cancer. 2012 Mar;48(5):713–720.
   PubMed Web of Science ®Google Scholar
• Reid RM, Baran A, Friedberg JW, et al. Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective. Cancer Med. 2016 Nov;5(11):3059–3067.
   PubMed Web of Science ®Google Scholar
• Cheung MC, Hay AE, Crump M, et al. Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12. J Natl Cancer Inst. 2015 Jul;107(7).
   Google Scholar
• Kymes SM, Pusic I, Lambert DL, et al. Economic evaluation of plerixafor for stem cell mobilization. Am J Manag Care. 2012 Jan;18(1):33–41.
   PubMed Web of Science ®Google Scholar
• Maziarz RT, Hao Y, Guerin A, et al. Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2018 May;59(5):1133–1142.
   PubMed Web of Science ®Google Scholar
• Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. 2019;10:2040620719841581.
   Web of Science ®Google Scholar
• Chow VA, Shadman M, Gopal AK. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood. 2018 Aug 23;132(8):777–781.
   PubMed Web of Science ®Google Scholar
• O’Leary MC, Lu X, Huang Y, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res off J Am Assoc Cancer Res. 2019 Feb 15;25(4):1142–1146.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018 Feb 1;378(5):439–448.
   PubMed Web of Science ®Google Scholar
• Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 Anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017 Jan 4;25(1):285–295.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Gordon LI, Palomba ML, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J Clin Oncol. 2018;36(15_suppl):7505.
   Web of Science ®Google Scholar
• Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018 Jan;15(1):31–46.
   PubMed Web of Science ®Google Scholar
• Havard R, Stephens DM. Anti-CD19 chimeric antigen receptor T cell therapies: harnessing the power of the immune system to fight diffuse large B cell lymphoma. Curr Hematol Malig Rep. 2018 Dec;13(6):534–542.
   PubMed Web of Science ®Google Scholar
• Corporation NP. Prescribing Information: kymriah; 2019. Available from: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/kymriah.pdf
   Google Scholar
• Kite Pharma I. Prescribing Information: yescarta; 2019. Available from: https://www.gilead.com/-/media/files/pdfs/medicines/oncology/yescarta/yescarta-pi.pdf
   Google Scholar
• Palomba ML, Garcia J, Wang L, et al. TRANSCEND: lisocabtagene maraleucel (liso-cel; JCAR017) healthcare resource utilization in patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 2018;132(Suppl 1):3545.
   Google Scholar
• Chabannon C, Kuball J, McGrath E, et al. CAR-T cells: the narrow path between hope and bankruptcy?. Bone Marrow Transplant. 2017 Dec;52(12):1588–1589.
   PubMed Web of Science ®Google Scholar
• Stadtmauer E, Mangan PA. CAR T-cell therapy: on the verge of breakthrough in many hematologic malignancies. J Adv Pract Oncol. 2017 Apr;8(3):228–231.
   PubMedGoogle Scholar
• Cavallo J. Weighing the cost and value of CAR T-cell therapy: a roundtable discussion With Carl H. June, MD; Sagar Lonial, MD; David G. Maloney, MD, PhD; and Pascal Touchon The ASCO Post; 2018 [cited 2019]. Available from: https://www.ascopost.com/issues/may-25-2018/weighing-the-cost-and-value-of-car-t-cell-therapy/
   Google Scholar
• Flowers CR, Ramsey SD. What can cost-effectiveness analysis tell us about chimeric antigen receptor T-cell therapy for relapsed acute lymphoblastic leukemia?. J Clin Oncol. 2018 Oct;2:Jco2018793570.
   Google Scholar
• Prasad V, De Jesús K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017 Jun;14(6):381–390.
   PubMed Web of Science ®Google Scholar
• Costantini S, Walensky RP. The costs of drugs in infectious diseases: branded, generics, and why we should care. J Infect Dis. 2019 Mar 19.
   PubMedGoogle Scholar
• Yip A, Webster RM. The market for chimeric antigen receptor T cell therapies. Nat Rev Drug Discov. 2018 Mar;17(3):161–162.
   PubMed Web of Science ®Google Scholar
• Helwick C. NCCN roundtable tackles issues with innovative immunotherapies The ASCO post; 2019. Available from: https://www.ascopost.com/issues/may-25-2019/nccn-roundtable-tackles-issues-with-innovative-immunotherapies/
   Google Scholar
• Snider J, Brauer M, Hao Y, et al. The economic value of CTL019 THERAPY FOR PEDIATRIC patients with relapsed and refractory acute lymphoblastic leukemia in the United Kingdom. Blood. 2017;130(Suppl 1):1330.
   Google Scholar
• Hao Y, Eldjerou LK, Yang H, et al. Cost-effectiveness analysis of CTL019 for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia in the United States. Blood. 2017;130(Suppl 1):609.
   Google Scholar
• Lin JK, Lerman BJ, Barnes JI, et al. Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. J Clin Oncol. 2018 Sep 13;36(32):3192–3202.
   Google Scholar
• Sarkar RR, Gloude NJ, Schiff D, et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. J Natl Cancer Inst. 2018 Dec 14;111(7):1–8.
   PubMedGoogle Scholar
• Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia. JAMA Pediatr. 2018 Dec 1;172(12):1161–1168.
   PubMed Web of Science ®Google Scholar
• NICE. National Insitute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years; 2018 [cited 2019]. Available from: https://www.nice.org.uk/guidance/ta554/chapter/3-Committee-discussion#costeffectiveness-estimate
   Google Scholar
• Tice JA, Walsh JME, Otuonye I, et al. Institute for Clinical and Economic Review: Chimeric Antigen Receptor T-Cell Therapy for BCell Cancers: Effectiveness and Value; 2018.
   Google Scholar
• Roth JA, Sullivan SD, Lin VW, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018 Dec;21(12):1238–1245.
   PubMed Web of Science ®Google Scholar
• NICE. National Institute for Health and Care Excellence. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies; 2019. Available from: https://www.nice.org.uk/guidance/ta559/chapter/3-Committee-discussion#cost-effectiveness
   Google Scholar
• NICE. National Institute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies; 2019. Available from: https://www.nice.org.uk/guidance/ta567/chapter/3-Committee-discussion#cost-effectiveness
   Google Scholar
• Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term survival and cost-effectiveness associated with axicabtagene Ciloleucel vs Chemotherapy for treatment of B-cell lymphoma. JAMA Network Open. 2019 Feb 1;2(2):e190035.
   PubMed Web of Science ®Google Scholar
• Lin JK, Muffly LS, Spinner MA, et al. Cost effectiveness of chimeric antigen receptor T-Cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J Clin Oncol. 2019 Aug 20;37(24):2105–2119.
   Google Scholar
• Bach PB, Giralt SA, Saltz LB. FDA approval of tisagenlecleucel: promise and complexities of a $475000 cancer drug. Jama. 2017 Nov 21;318(19):1861–1862.
   PubMed Web of Science ®Google Scholar
• Worcester S. CAR T-cell therapy: moving from cost to value; 2017. Available from: https://www.mdedge.com/hematologynews/nhlhub/article/152563/all/car-t-cell-therapy-moving-cost-value
   Google Scholar
• CMS. CMS proposes Coverage with Evidence Development for Chimeric Antigen Receptor (CAR) T-cell Therapy; 2019. Available from: https://www.cms.gov/newsroom/press-releases/cms-proposes-coverage-evidence-development-chimeric-antigen-receptor-car-t-cell-therapy
   Google Scholar
• CMS. CMS STATEMENT: delay in final Chimeric Antigen Receptor (CAR) T-cell therapy national coverage determination; 2019. Available from: https://www.cms.gov/newsroom/press-releases/cms-statement-delay-final-chimeric-antigen-receptor-car-t-cell-therapy-national-coverage
   Google Scholar
• CMS. Fiscal Year (FY) 2020 Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long Term Acute Care Hospital (LTCH) prospective payment system proposed rule and request for information; 2019. Available from: https://www.cms.gov/newsroom/fact-sheets/fiscal-year-fy-2020-medicare-hospital-inpatient-prospective-payment-system-ipps-and-long-term-acute
   Google Scholar
• Atilla E, Kilic P, Gurman G. Cellular therapies: day by day, all the way. Transfus Apher Sci. 2018 Apr;57(2):187–196.
   PubMed Web of Science ®Google Scholar
• Baruch EN, Berg AL, Besser MJ, et al. Adoptive T cell therapy: an overview of obstacles and opportunities. Cancer. 2017 Jun 1;123(S11):2154–2162.
   PubMedGoogle Scholar
• Zhao J, Song Y, Liu D. Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. J Hematol Oncol. 2019;12(1):17.
   PubMedGoogle Scholar
• Cohen JB, Kurtz DM, Staton AD, et al. Next-generation surveillance strategies for patients with lymphoma. Future Oncol. 2015;11(13):1977–1991.
   PubMed Web of Science ®Google Scholar
• Hicks LK, Bering H, Carson KR, et al. The ASH Choosing Wisely(R) campaign: five hematologic tests and treatments to question. Blood. 2013 Dec 5;122(24):3879–3883.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol. 2015 Mar;4(1):5.
   PubMed Web of Science ®Google Scholar
• Cheung MC, Mittmann N, Earle CC, et al. Are we Choosing Wisely in lymphoma? Excessive use of surveillance CT imaging in patients with Diffuse Large B-cell Lymphoma (DLBCL) in long-term remission. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e27–e34.
   PubMed Web of Science ®Google Scholar
• Huntington SF, Svoboda J, Doshi JA. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission. J Clin Oncol. 2015 May 1;33(13):1467–1474.
   PubMed Web of Science ®Google Scholar